Find out now if you qualify. Time is limited to file a claim. You may be entitled to compensation. Fill out the form below to see if you qualify.
Patients At Risk
Information submitted will be transmitted to a law firm. This communication is intended to be an attorney-client communication for purposes of evaluating your claim and will be kept confidential by the law firm. The communication does not create an attorney-client relationship and no relationship is formed until a fee agreement is signed by you and the law firm. I also have read and agree to your Privacy Policy
April 2022: The MDL Paraquat class action judge will have a status conference on April 1st to review where the litigation is headed and how best to take the bellwether lawsuits forward for trial in November 2022. 44 new paraquat lawsuits have been added to the MDL in the last two weeks. At this pace, April 2022 will be the busiest month for new files yet. Last week, the parties filed their class-action bellwether picks with the Paraquat MDL judge. Those choices, however, have not been made public.
May 2022: In the last month, over 50 new cases have been added to the Paraquat Lawsuit Multidistrict Litigation (MDL). A group of six patients was recently selected by the Paraquat MDL court for the initial Paraquat Parkinson's disease bellwether trials. As a result, the first trial in November 2022 is approaching soon. The strategy is to select 16 paraquat claims from among the almost 1000 Parkinson's disease litigation claims filed. Following some limited fact discovery in these instances, paraquat attorneys on both sides submitted a preference list to the MDL court, ranking the 16 cases in order of priority. Attorneys for plaintiffs seek the finest facts for their clients, while defense attorneys want the worst. The judge whittled the list down to six Paraquat claims based on these rankings.
CLAIM UPDATES
How We Can Help
We offer a free, confidential consultation to discuss what happened and whether you may be entitled to compensation for medical bills, lost income, pain and suffering, and—where applicable—wrongful death damages. Start your free claim review today by filling out the form above.
Seek Justice Today
Maryland Juvenile Detention
Abuse Claim Help
Jeff Brandow
Sexual Abuse
Claim Help
File Your Claim Now
If you or a loved one suffered blood clots, ischemic stroke, cardiac arrest, or death after receiving Andexxa (andexanet alfa), you may have legal options. Andexxa is an IV medication used in emergency settings to reverse certain blood thinners when a patient has life-threatening or uncontrolled bleeding. If serious complications occurred after treatment, our team can review your medical records, the timing of events, and whether the risks were appropriately evaluated, monitored, and communicated.
When you reach out, we start with a confidential intake to understand what happened, when Andexxa was given, and what complications followed. We then obtain and review the key medical records—such as ER and hospital charts, medication administration records, imaging, labs, and discharge summaries—to build a clear timeline and identify evidence supporting the claim. Next, we investigate who may be legally responsible and evaluate potential legal theories based on the facts, including whether risks were adequately warned about, monitored, or addressed in the patient’s care. We also document damages by gathering proof of medical costs, lost income, long-term limitations, and—when applicable—wrongful death losses. Once the claim is ready, we handle all communications with insurers and defense counsel, file the appropriate lawsuit or settlement demand, and pursue compensation through negotiation, litigation, and trial if necessary—all while keeping you informed at each stage and working to move the case forward as efficiently as possible.
"Trust our experienced team to handle your claim with care and commitment. Contact us today for reliable legal support."
Our dedicated team will fight for your rights and compensation. Confidentiality, Safety, & Justice are our top priorities
How to Qualify for a Depo-Provera Claim:
Use of Depo-Provera
Diagnosis of Brain Tumor
Document Evidence
Submit The Form Above
Depo-Provera is an injectable birth control containing the synthetic hormone medroxyprogesterone acetate, is linked to an increased risk of meningioma, a rare brain tumor. This risk was not adequately disclosed to consumers or medical professionals. Studies, including those published in the Journal of the American Medical Association (JAMA), have shown that long-term use of Depo-Provera significantly raises the risk of developing meningiomas.
Claims against Pfizer, Inc., the drug’s manufacturer, alleges that the company knew or should have known about the increased risk of meningiomas—brain tumors that can cause severe neurological symptoms—especially with prolonged use. The claims state that Pfizer failed to adequately warn doctors and patients, rushed the drug to market without sufficient long-term studies, and prioritized profits over safety.
Due to the rising number of claims against Pfizer regarding Depo-Provera and brain tumors have been consolidated into multidistrict litigation (MDL) in federal court. Affected individuals may seek compensation for medical expenses, long-term care, and other damages, with the potential for federal court consolidation of cases.
Andexxa Injury Help
Justice & Compensation - Start Here
Who May Qualify to File a Claim
You may be eligible to pursue a case if you (or a family member) received Andexxa and then experienced a serious clotting or cardiac event—such as DVT/PE, ischemic stroke, heart attack, cardiac arrest, or death—and the medical timeline supports a connection worth investigating. Because patients receiving Andexxa often have complex medical histories, eligibility typically depends on details like the indication for Andexxa, dosing and monitoring, anticoagulation restart decisions, the timing of the adverse event, and documentation in hospital records.
By clicking the “Submit” button below, I hereby grant my express written consent and authorize Tort Group LLC, and its affiliates and law firm partners, to contact me about their services at the phone number and email address provided above/below. I consent to receive telemarketing calls and text messages using an automatic telephone dialing system or prerecorded voice. I understand that the express written consent I provide here is not required in order to purchase any good or service. I also acknowledge and agree to the Terms & Conditions. Text Message frequency may vary. Message & Data rates may apply. You may opt-out of SMS at any time by replying STOP to the phone number we texted you from. Reply HELP for help to the phone number we texted you from.. You may view our Privacy Policy here.
Why Andexxa Was Removed From Market
Andexxa was approved for patients taking rivaroxaban (Xarelto) or apixaban (Eliquis) when doctors needed rapid reversal of anticoagulation due to life-threatening or uncontrolled bleeding.The FDA initially granted accelerated approval to Andexxa in 2018, based on a lab measurement doctors use as an indirect sign the drug is working (instead of proving it improves real patient outcomes), while requiring a randomized trial to confirm clinical benefit. In a December 2025 FDA safety communication, the agency stated that it had received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, and that—based on available data—the FDA considered the risks to outweigh the benefits. The FDA noted AstraZeneca submitted a request to voluntarily withdraw the biologics license application, and the company confirmed it would end U.S. commercial sales by December 22, 2025, meaning Andexxa would no longer be manufactured for or sold in the U.S. after that date. Clinical and postmarketing data describe significant thrombotic and mortality outcomes in patients treated with Andexxa. In the ANNEXA-4 study (published in The New England Journal of Medicine), within 30 days of treatment, death occurred in 49 patients (14%) and a thrombotic event occurred in 34 patients (10%). In the FDA’s discussion of safety findings from the required randomized trial in intracerebral hemorrhage (ANNEXA-I), the agency highlighted a higher incidence of thrombosis in the Andexxa arm (14.6%) versus usual care (6.9%), and thrombosis-related deaths at day 30 of 2.5% vs 0.9% (reported as 6 patients vs 2 patients, respectively).
